Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety
Article structure
This article is organized to (1) summarize the clinical need in type 1 diabetes (T1D) with chronic kidney disease (CKD); (2) describe the FINE‑ONE trial design; (3) present and interpret primary efficacy and safety data; (4) place findings in context of existing evidence and biologic rationale; and (5) discuss clinical implications, limitations, and next steps.
Highlights
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.